CV-1808

CaptionSynonyms

CV-1808

Drug Information
Image
Identifiers CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name		Chemical Data C H N O Molecular Weight

CV-1808 is a pharmacological compound that has been studied for its potential therapeutic effects in various medical conditions. It is primarily known for its role as a selective agonist of the alpha-2 adrenergic receptor, which is a class of G protein-coupled receptors involved in the modulation of neurotransmitter release in the central and peripheral nervous systems.

Pharmacodynamics

CV-1808 acts by binding to the alpha-2 adrenergic receptors, which are predominantly located in the presynaptic nerve terminals. Activation of these receptors leads to a decrease in the release of norepinephrine, thereby exerting an inhibitory effect on the sympathetic nervous system. This mechanism is beneficial in conditions where sympathetic overactivity is a concern, such as hypertension and certain types of anxiety disorders.

Pharmacokinetics

The pharmacokinetic profile of CV-1808 includes its absorption, distribution, metabolism, and excretion. While specific data on CV-1808 may be limited, drugs in this class typically exhibit moderate bioavailability and are metabolized in the liver. The elimination half-life can vary depending on the specific formulation and route of administration.

Clinical Applications

Research into CV-1808 has explored its potential use in managing conditions such as hypertension, due to its ability to reduce peripheral vascular resistance. Additionally, its anxiolytic properties have been investigated in the context of anxiety disorders, where it may help alleviate symptoms by modulating adrenergic activity.

Side Effects

As with other alpha-2 adrenergic agonists, CV-1808 may cause side effects such as sedation, dry mouth, and hypotension. These effects are generally dose-dependent and can be managed by adjusting the dosage or frequency of administration.

Research and Development

Ongoing research is focused on further elucidating the therapeutic potential of CV-1808, particularly in combination with other pharmacological agents. Studies are also examining its long-term safety profile and efficacy in diverse patient populations.

Also see

• Alpha-2 adrenergic receptor
• Adrenergic agonist
• Hypertension
• Anxiety disorder